| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/1346-8138.13275 |
| P698 | PubMed publication ID | 26972733 |
| P50 | author | Minoru Hasegawa | Q79284164 |
| Manabu Fujimoto | Q89796111 | ||
| P2093 | author name string | Takaaki Ito | |
| Yasuhiro Nakamura | |||
| Masahiro Hayashi | |||
| Masakazu Kawaguchi | |||
| Masakazu Takahara | |||
| Hiroshi Fujiwara | |||
| Takafumi Kadono | |||
| Takeshi Nakanishi | |||
| Yoshihide Asano | |||
| Yuji Inoue | |||
| Akira Hashimoto | |||
| Keisuke Sakai | |||
| Hironobu Ihn | |||
| Miki Tanioka | |||
| Mikio Ohtsuka | |||
| Masatoshi Abe | |||
| Shinichi Imafuku | |||
| Tamihiro Kawakami | |||
| Andres Le Pavoux | |||
| Fumihide Ogawa | |||
| Koma Matsuo | |||
| Masaki Ohtsuka | |||
| Masanari Kodera | |||
| Naoki Madokoro | |||
| Osamu Yamasaki | |||
| Ryokichi Irisawa | |||
| Ryuichi Kukino | |||
| Taiki Isei | |||
| Takao Tachibana | |||
| Takayuki Ishii | |||
| Takeo Maekawa | |||
| Takeshi Kono | |||
| Wound/Burn Guidelines Committee | |||
| Yuichiro Yoshino | |||
| P2860 | cites work | Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study | Q24816844 |
| Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke | Q28167141 | ||
| A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) | Q28174751 | ||
| Management of antiphospholipid antibody syndrome: a systematic review | Q28195454 | ||
| Prophylaxis of the antiphospholipid syndrome: a consensus report | Q28196923 | ||
| Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals | Q28217805 | ||
| Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial | Q30829854 | ||
| Effects of cilostazol in patients with Raynaud's syndrome. | Q33195315 | ||
| Calcinosis in rheumatic diseases | Q33216664 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients | Q33369688 | ||
| Intravenous immunoglobulin therapy in antiphospholipid syndrome | Q33369796 | ||
| Use of rituximab in the antiphospholipid syndrome | Q33389337 | ||
| Antiphospholipid syndrome and the skin | Q33499667 | ||
| Clinical and serological features of severe vasculitis in rheumatoid arthritis: prognostic implications | Q33560395 | ||
| Benign cutaneous polyarteritis nodosa in children below 10 years of age--a clinical experience | Q33567028 | ||
| Dermatomyositis presenting as panniculitis | Q33848590 | ||
| Cutaneous lupus erythematosus | Q34222398 | ||
| Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 | ||
| Bilateral anterior toxic optic neuropathy and the use of infliximab | Q34810954 | ||
| Causes, investigation and treatment of leg ulceration | Q35090990 | ||
| ICAM-1, E-selectin, and TNF alpha expression in labial salivary glands of patients with rheumatoid vasculitis | Q35546880 | ||
| Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression? | Q35547797 | ||
| Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis | Q35552273 | ||
| Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline | Q35552480 | ||
| Low dose warfarin treatment for calcinosis in patients with systemic sclerosis | Q35553349 | ||
| Radiological hand involvement in systemic sclerosis | Q35637515 | ||
| High-dose intravenous immunoglobulin infusion in polyarteritis nodosa: report on one case and review of the literature | Q36290629 | ||
| Leg ulcers: uncommon presentations | Q36329764 | ||
| New treatments for antiphospholipid syndrome | Q36408003 | ||
| C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab | Q36915951 | ||
| Panniculitis, infection, and dermatomyositis: case and literature review | Q37440766 | ||
| Surgery for scleroderma of the hand | Q39303699 | ||
| Rheumatoid vasculitis: experience with 13 patients and review of the literature | Q39313917 | ||
| Rheumatoid vasculitis: diagnostic and therapeutic decisions | Q39350687 | ||
| Management of sclerodermal finger ulcers | Q39351914 | ||
| Leg ulcers in patients with rheumatoid arthritis--a prospective study of aetiology, wound healing and pain reduction after pinch grafting | Q39416248 | ||
| Efficacy of filtration leukocytapheresis on rheumatoid arthritis with vasculitis | Q39500809 | ||
| Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis | Q39576780 | ||
| Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. | Q39638832 | ||
| Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. | Q39702715 | ||
| Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril | Q39819362 | ||
| Improved rheumatoid digital vasculitis in a patient treated with TNFalpha agent blocking (infliximab). | Q39847141 | ||
| Long-term results of periarterial sympathectomy | Q39897064 | ||
| Vesiculobullous systemic lupus erythematosus. Report of two cases and a review of the literature | Q40163690 | ||
| Carboxylated calcium-binding proteins and vitamin K. | Q40283389 | ||
| Dermatomyositis treated with high-dose intravenous immunoglobulins and associated with panniculitis | Q40948352 | ||
| Proceedings: Controlled trial of azathioprine in rheumatoid vasculitis | Q41317813 | ||
| Parathyroid hormone and calcium metabolism in generalized scleroderma. Increased PTH level and secondary hyperparathyroidism in patients with aberrant calcifications. Prophylactic treatment of calcinosis | Q41595380 | ||
| Treatment of calcinosis with diltiazem | Q41653608 | ||
| Clinical entity of Lupus erythematosus panniculitis/lupus erythematosus profundus | Q42448195 | ||
| Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis | Q43048503 | ||
| Successful treatment of severe rheumatoid vasculitis by infliximab | Q43050448 | ||
| Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate | Q43209496 | ||
| Treatment of polyarteritis nodosa with dapsone | Q43517961 | ||
| New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment | Q43601137 | ||
| Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis | Q44124048 | ||
| Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis | Q44313365 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks | Q44774931 | ||
| Granulocyte adsorptive apheresis for leg ulcers complicated by rheumatoid arthritis: a report on three successfully treated cases | Q45107349 | ||
| Leukocytapheresis treatment for pyoderma gangrenosum | Q45148816 | ||
| Reversible lower limb lymphedema as the first manifestation of cutaneous periarteritis nodosa | Q45216398 | ||
| Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis | Q45217518 | ||
| Vitamin D, parathyroid hormone, and acroosteolysis in systemic sclerosis | Q46324731 | ||
| Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients | Q46761996 | ||
| Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy | Q48501531 | ||
| Bosentan as a rescue therapy in scleroderma refractory digital ulcers | Q48591305 | ||
| Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects. | Q50652171 | ||
| Prevention of amputation caused by rheumatic diseases following a novel therapy of exposing bone marrow, occlusive dressing and subsequent epidermal grafting. | Q51497313 | ||
| Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. | Q53354829 | ||
| Filtration leukocytapheresis therapy in the treatment of rheumatoid arthritis patients resistant to or failed with methotrexate. | Q53894956 | ||
| Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis. | Q54058396 | ||
| Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. | Q54573513 | ||
| Autoimmune Diseases Induced by TNF-Targeted Therapies | Q56907567 | ||
| P433 | issue | 7 | |
| P921 | main subject | connective tissue | Q25615 |
| P304 | page(s) | 729-757 | |
| P577 | publication date | 2016-03-12 | |
| P1433 | published in | The Journal of Dermatology | Q18225322 |
| P1476 | title | The wound/burn guidelines - 4: Guidelines for the management of skin ulcers associated with connective tissue disease/vasculitis | |
| P478 | volume | 43 |
| Q90747126 | Comprehensive Proteomic Profiling of Pressure Ulcers in Patients with Spinal Cord Injury Identifies a Specific Protein Pattern of Pathology |
| Q64102968 | Idiopathic inflammatory myopathies: narrative review of unmet needs in clinical practice guidelines |
| Q58602905 | Mixed connective tissue disease: state of the art on clinical practice guidelines |
| Q58602910 | Systemic sclerosis: state of the art on clinical practice guidelines |
Search more.